Tina Cleary
Retina Specialist · Boston, MANPI 1649243221
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Tarsus Pharmaceuticals, Inc. at 28.4% of the total. That places this record below the midpoint for retina specialist clinicians in MA, where the typical reported total is $806.
Across 7 payments — averaging $26.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$52
- Dompe US, Inc.$34
- Sun Pharmaceutical Industries Inc.$30
- Regeneron Healthcare Solutions, Inc.$29
- Novartis$23
- Bausch & Lomb Americas Inc.$16
What the payments were for
- Food & beverage$184100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 2 | $52 |
| Dompe US, Inc. | 1 | $34 |
| Sun Pharmaceutical Industries Inc. | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Novartis | 1 | $23 |
| Bausch & Lomb Americas Inc. | 1 | $16 |
How this compares
$184 in reported general payments places this provider in the 25th percentile of 26 retina specialist providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 118 | $7,080 |
| Ketorolac Tromethamine | 68 | $2,060 |
| Bromfenac Sodium | 11 | $1,307 |
| Timolol Maleate | 21 | $970 |
| Latanoprost | 55 | $790 |
| Ofloxacin | 35 | $526 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 36 | $507 |
| ErythromycinErythromycin Base | 41 | $486 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Boston
- Jeffrey HeierBoston$1.5M
- Andre WitkinBoston$23K
- Chirag ShahBoston$14K
- Brian BalliosBoston$3K
- Ilya LeskovBoston$2K
- Siamak ShokrollahiBoston$806
- Omar AbdelalBoston$806
- Xiang WerdichBoston$686
- Mohamed ElmasryBoston$190
- Miriam Englander Paschalis IliosBoston$170
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.